Home India Ministry of Health and Family Welfare Drug Alert for the Month of Revised March 2023...
Date: 2024-02-21 Category: Not Applicable State: Union Government Country: India

Drug Alert for the Month of Revised March 2023

Issued by Ministry of Health and Family Welfare · Central Drugs Standard Control Organization

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task

Executive Summary & Key Takeaways

What it means

  • This is a drug alert for March 2023 (Revised) listing drugs, medical devices, vaccines, and cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded.
  • The gazette specifically mentions one drug, DACILON 0.5 (Dactinomycin for Injection USP 0.5 mg), manufactured by Celon Laboratories Pvt. Ltd.

Key Changes

  • DACILON 0.5 (Dactinomycin for Injection USP 0.5 mg), batch number DMI22412/203AC22, with a manufacturing date of 11/2022 and expiry date of 11/2025, manufactured by Celon Laboratories Pvt. Ltd. is listed.
  • The reason for inclusion is that while the sample was declared as Standard Quality regarding Appearance & Assay by CDL, Kolkata as per Form-2 report no. 2-1/2023-SS/CC-169/715 dated 10.10.2023, it is subject to the outcome of further investigation.

Impact Analysis

Impact on Celon Laboratories Pvt. Ltd.

  • Financial impact due to potential recalls, legal fees, and loss of sales.

Suggested Action Items for Celon Laboratories Pvt. Ltd.

  • Communicate transparently with stakeholders, including regulatory authorities, healthcare professionals, and patients.

Impact on Healthcare Professionals

  • Potential need to consider alternative medications if concerns about the drug's quality persist.

Suggested Action Items for Healthcare Professionals

  • Report any suspected adverse events to the appropriate regulatory authorities.

Impact on Patients

  • Need to be vigilant for any unusual side effects or symptoms.

Suggested Action Items for Patients

  • Report any suspected adverse events to their healthcare provider and the appropriate regulatory authorities.

Key Entities Referenced

DACILON 0.5 (Dactinomycin for Injection USP 0.5 mg): A drug manufactured by Celon Laboratories Pvt. Ltd. that is subject to further investigation regarding its quality. Celon Laboratories Pvt. Ltd.: The manufacturer of DACILON 0.5 (Dactinomycin for Injection USP 0.5 mg), located in Telangana, India. CDSCO: Central Drugs Standard Control Organisation CDL, Kolkata: Central Drugs Laboratory, Kolkata, which conducted the initial quality testing. Form-2: A standard form related to drug testing and analysis.
Official Source Record View Original Source →
See Full Document Text
Drug Alert for the Month of March – 2023 (Revised) List of Drugs, Medical Devices, Vaccine and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/Misbranded for the Month of March– 2023 (Revised) S.No Name of Batch No. Date of Date of Manufactured By Reason for Drawn By From Remarks Drugs/medical Manufa Expiry failure (Name of device/cosmetics cture the Laboratory) 10. As per Form-2 (CDL, Kolkata) Celon Laboratories report no. 2-1/2023-SS/CC- Pvt. Ltd., Plot No.2, 169/715 dated 10.10.2023, the DACILON 0.5 ALEAP Industrial subject sample declared as (Dactinomycin DMI224 12/20 Estate, Appearance CDSCO CDL, 11/2025 Standard Quality in regard to for Injection USP 3AC 22 Gajularamaram, & Assay Hyderabad Kolkata the test for “Appearance & 0.5 mg) Medchal Dist. Assay”, however, the same is 500090, Telangana subject to outcome of further State, India. investigation. Page 1 of 1

Continue your research